CTOP ,> = 97 %( HPLC)

Code: p5296-1mg D2-231

Non disponible en dehors du Royaume-Uni et de l'Irlande

Amino Acid Sequence

Phe-Cys-Tyr-Trp-Orn-Thr-Pen-Thr-NH2 [Disulfide Bridge: 2-7]

Application

CTOP has been used:to study the anxiogenic effects in...


en savoir plus

Votre prix
£181.00 1MG
DEMANDER

Non disponible en dehors du Royaume-Uni et de l'Irlande

Amino Acid Sequence

Phe-Cys-Tyr-Trp-Orn-Thr-Pen-Thr-NH2 [Disulfide Bridge: 2-7]

Application

CTOP has been used:to study the anxiogenic effects induced by CTOP in mice and rat.to study the effect of μ-opioid antagonist, CTOP on the bovine milk-derived LF (BLF)-induced analgesia.to determine whether μ-opioid receptors act cooperatively with 5-hydroxytryptamine (5-HT1A) receptors to regulate the behaviors generated in the elevated T-maze (ETM).

Biochem/physiol Actions

D-Pen-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 (CTOP) inhibits acute morphine-induced hypermotility and analgesic effect of morphine in a dose-dependent manner in vivo.

Selective ligand for µ-opioid receptors.

General description

D-Pen-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 (CTOP) is a selective cyclic μ-opioid receptor antagonist.

Linkage

Somatostatin analog

assay≥97% (HPLC)
formpowder
Gene Informationmouse ... Pnoc(18155)
InChI keyPZWWYAHWHHNCHO-FGHAYEPSSA-N
InChI1S/C50H67N11O11S2/c1-26(62)39(42(53)65)59-49(72)41-50(3,4)74-73-25-38(58-43(66)33(52)21-28-11-6-5-7-12-28)47(70)56-36(22-29-16-18-31(64)19-17-29)45(68)57-37(23-30-24-54-34-14-9-8-13-32(30)34)46(69)55-35(15-10-20-51)44(67)60-40(27(2)63)48(71)61-41/h5-9,11-14,16-19,24,26-27,33,35-41,54,62-64H,10,15,20-23,25,51-52H2,1-4H3,(H2,53,65)(H,55,69)(H,56,70)(H,57,68)(H,58,66)(H,59,72)(H,60,67)(H,61,71)/t26-,27-,33-,35+,36+,37-,38+,39+,40+,41-/m1/s1
Quality Level100
SMILES stringC[C@@H](O)[C@H](NC(=O)[C@H]1NC(=O)[C@@H](NC(=O)[C@H](CCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](CSSC1(C)C)NC(=O)[C@H](N)Cc5ccccc5)[C@@H](C)O)C(N)=O
storage temp.−20°C
UniProt accession no.Q64387
Cas Number103429-31-8
Ce produit répond aux critères suivants: